Chris Lee, CEO of VentureBlick, Appointed Co-CEO of MediThinQ
Over 30 Years of Global Healthcare Leadership at Medtronic and Bayer
MediThinQ, a medical visualization solutions company, has appointed global healthcare executive Chris Lee (Hee Yeol Lee), CEO of VentureBlick, as its Co-CEO to accelerate its global business expansion.
On August 11, MediThinQ announced the launch of a co-CEO system with founder Seung Joon Im and Chris Lee at the helm. The company aims to combine its proprietary medical visualization technology and product competitiveness with Lee’s experience in global business strategy and organizational management, thereby accelerating overseas revenue growth and the enhancement of corporate value.
Lee, who has been serving as Chairman of the Board at MediThinQ, has led business growth and organizational innovation in the global healthcare industry for over 30 years. At Medtronic, he served as President of Asia-Pacific as well as President of China, Taiwan, and Hong Kong for about 10 years. He also oversaw Asia-Pacific and China business for approximately seven years at Bayer Healthcare. Notably, he was the first Asian executive in history to serve on the top management team of two Fortune 500 companies, and was appointed as the first Asian CEO in Bayer’s 150-year history.
Since 2022, he has established VentureBlick, a global growth and commercialization firm specializing in healthcare, supporting the global business development and growth of healthcare companies around the world. At MediThinQ, he will be responsible for overseas market expansion, building strategic partnerships, and advancing organizational and management systems.
As Co-CEO, Lim will continue to lead the company’s technological vision, product strategy, R&D, and core business operations. His plan is to strengthen technology development and product competitiveness, while linking these capacities to tangible global business achievements.
MediThinQ has already expanded product commercialization and overseas market entry by signing distribution and supply agreements with leading global healthcare companies such as Medtronic, Baxter, and Sinopharm in major markets including the United States and China. With the new co-CEO system, the company plans to bolster its global business execution and organizational capabilities, while accelerating investment attraction and preparations for an initial public offering (IPO).
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Lim stated, "While further sharpening our focus on technology and products, we will boldly accelerate the growth of our global business and organization. Our aim is to develop into a global medtech unicorn that demonstrates how Korea’s innovative medical technology can lead the global market." Lee said, "MediThinQ is a company whose technological and business capabilities have been proven, to the extent that it is chosen as a partner by world-class healthcare companies. We will further strengthen our global business strategy and organizational execution to expand overseas sales and our impact in global markets in earnest."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.